The activation of p38 by activated‐FGFR3 in bladder tumors contributes to malignant behavior and the inhibition of this activation may be of therapeutic value, as reported for an increasing number of cancers (Koul et al, 2013; Igea & Nebreda, 2015). Here, MAPK14 is linked to urinary bladder neoplasm.